Business
Valeo Pharma Announces Commercial Launch of Enerzair® Breezhaler® and Atectura® Breezhaler®
Valeo Pharma Announces Commercial Launch of Enerzair® Breezhaler® and Atectura® Breezhaler®.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nValeo Pharma Announces Commercial Launch of Enerzair® Breezhaler® and Atectura® Breezhaler®\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nValeo Pharma Announces Commercial Launch of Enerzair® Breezhaler® and Atectura® Breezhaler®\nCanada NewsWire\nMONTREAL, June 22, 2021\n\n\n\nProduct shipments have commenced across Canada National respiratory sales force recruitment well advanced, field deployment on-going Private and public reimbursement coverage progressing Nelly Komari, joins Valeo as Senior Vice President Scientific & Medical Affairs MONTREAL, June 22, 2021 /CNW/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, announced today that commercialization of Enerzair Breezhaler and Atectura Breezhaler has commenced following product shipments  across Canada and the initial deployment of its national respiratory sales force. \n\n \n \n \n \n \n \n\n \n\"The commercial launch of Enerzair Breezhaler and Atectura Breezhaler is a key milestone for Valeo. It marks the debut of the Company's commercial efforts in the $700M Canadian asthma market, one of Canada's largest therapeutic segments\", said Steve Saviuk, Chief Executive Officer. \" I am especially proud of our Valeo team that organized this major product launch less than three months after licensing the products from Novartis Pharmaceuticals Canada Inc.. The commercialization of these two innovative asthma therapies follows the successful launch of RedescaTM in April 2021 and will immediately impact our financial performance and accelerate in the fiscal quarters to come\".\nCommenting on the Enerzair Breezhaler and Atectura Breezhaler commercial launch, Frederic Fasano, President and Chief Operating Officer said; \"We are very excited to start promoting and selling our first respiratory products. The establishment of our country wide respiratory, medical and commercial infrastructure is well under way and it is driven by a team of highly skilled and experienced pharma professionals. ...